Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (April 2019)
26 slides from Eyepoint's investor presentation, Apr 1, 2019
Slide 1: Investor Presentation April 2019
NASDAQ: EYPT Investor Presentation April 2019 Exhibit 99.1
Slide 2: Forward Looking Safe Harbor Statements
Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for inve
Slide 3: EyePoint Highlights: Transformational Opportunity in Ophthalmology
Acquired Icon Bioscience to transform business and accelerate growth Launched YUTIQTM (Feb 4, 2019) and DEXYCUTM (Mar 12, 2019) (J-Code reimbursement in place for both products) Established a strong leadership team with seasoned executives to lead our commercial strategy and manage our sales infrast
Slide 4: Management with Proven Commercial Track Record & Highly Experienced Board of Directors
Management with Proven Commercial Track Record & Highly Experienced Board of Directors Dr. Göran Ando Chairman of the Board Dr. David J Mazzo Director Nancy Lurker President and CEO Dr. John Landis Director Doug Godshall Director Dr. Jay Duker Director Dr. David Guyer Director Ron Eastman Director B
Slide 5: Durasert: Approved Technology for Ocular Delivery
Durasert™: Approved Technology for Ocular Delivery EyePoint is one of few companies that has developed FDA-approved extended-release inserts EyePoint will continue to evaluate potential partnerships that utilize Durasert technology OZURDEX (2009, Allergan) BRVO, CRVO, NIU, DME RETISERT (2005, B&L) U
Slide 6: EyePoint Pharmaceuticals' Product Pipeline
EyePoint Pharmaceuticals' Product Pipeline Product / Program Preclin. Phase 1 Phase 2 Phase 3 Approval Market Rights DEXYCU™ post-operative inflammation Launched Mar 12, 2019 WW YUTIQ™ three-year treatment for chronic non-infectious uveitis affecting the posterior segment Launched Feb 4, 2019 U.S.(1
Slide 7: DEXYCU & YUTIQ Commercialization Roadmap
DEXYCUTM & YUTIQTM Commercialization Roadmap Medical Education Plan Rolled Out Multiple KOL Advisory Boards & significant presence at key Congresses Robust Publication plan and key papers published with continued data flow MSL team complete Contract Sales Organization in Place (44 reps in total) Ded
Slide 8: Postoperative inflammation following ocular surgery
Postoperative inflammation following ocular surgery
Slide 9: DEXYCU Market
DEXYCUTM Market 8% annual growth rate in the U.S. Most performed surgery in the U.S. Cataract surgeries per year 4.8 Million* Baby boomers; longer life expectancy Improvements to intraocular lenses (IOLs) Experienced surgeons * Based upon company estimates for 2018. Source: imaged from the American
Slide 10: Current Post-Cataract Regimen Requires Polypharmacy and Places Significant Burden
Current Post-Cataract Regimen Requires Polypharmacy and Places Significant Burden on Patients and Physician Offices * Source: Vigamox/Besivance product labeling (not specifically indicated for this use, but are commonly prescribed for use). ** Source: Prolenza/Bromday product labeling (not specifica
Slide 11: DEXYCU (dexamethasone intraocular suspension) 9%
DEXYCUTM (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation Single dose (5mL) administered in the posterior chamber (behind the iris) at the end of surgery Encapsulated in bioerodible Verisome® technology for extended release of dexamethasone Wong
Slide 12: DEXYCU Rapidly Reduces Inflammation with Statistical Significance
DEXYCUTM Rapidly Reduces Inflammation as Early as Day 1 with Statistical Significance at Day 3 through Day 30 * *P≤0.05 vs placebo Day 8 Primary endpoint Placebo (n=80) DEXYCU™ (n=156) * * * Note: Refer to the full DEXYCU™ product label at www.eyepointpharma.com. 3x clearance vs. placebo at day 8 40
Slide 13: Phase 3 Study 13-04 Safety Results
Phase 3 Study 13-04 Safety Results Safety, n (%) Placebo N=80 517 mcg N=156 Any TEAE in study eye 51 (63.8) 72 (46.2) Any ocular SAE in study eye 0 0 Any non-ocular SAE 4 (5.0) 4 (2.6) Study Eye AEs Occurring in ³5% of At Least One Active Treatment Group Intraocular pressure increased 7 (8.8) 21 (13
Slide 14: DEXYCU Commercial Launch Approach
DEXYCUTM Commercial Launch Approach Launched on March 12, 2019 Suppresses inflammation Offsets eyedrop burden / limits potential patient confusion Patients typically required to pay out of pocket for eyedrops Ease of use / non-disruptive to existing surgical practice Potential improvement in complia
Slide 15: DEXYCU Market Research
DEXYCUTM Market Research Market Survey Involving Over 100 Cataract Surgeons Shows High Intent To Use Indicated Intent to Use Likelihood to Recommend Appropriate Patient Population 86% indicated intent to use 72% of patients would be appropriate candidates* 87% would recommend to a colleague upon com
Slide 16: Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Slide 17: YUTIQ Market
YUTIQTM Market Sight-threatening inflammatory disease ~30,000 new cases of blindness per year in the U.S. Uveitis is inflammation of the uveal tract (iris, ciliary body, choroid) or adjacent structures (lens, retina, vitreous, optic nerve) Uveitis can be acute or chronic and the flares of inflammati
Slide 18: YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg
YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg for chronic non-infectious uveitis affecting the posterior segment of the eye YUTIQ provides consistent micro dosing of corticosteroid up to three years without drug peaks and valleys and has been shown to significantly decrease the recurr
Slide 19: Primary Efficacy Endpoint: Recurrence Rate at 6 and 12 Months
Primary Efficacy Endpoint: Recurrence Rate at 6 and 12 months Study 1 (Recurrence Rate at 6 and 12 Months) Study 2 (Recurrence Rate at 6 and 12 Months) 4.4x 3.1x p < 0.01 p < 0.01 p < 0.01 p < 0.01 YUTIQ Patients more likely to be recurrence free * Sham includes standard of care. Note: Refer to the
Slide 20: Reduced Probability of Uveitis Recurrence After a Single YUTIQ Insert
Reduced Probability of Uveitis Recurrence Through 24 Months After a Single YUTIQ™ FA Insert (STUDY PSV-FAI-001) ITT Population Note: Sham patients include patients that received rescue therapy. Reduced the rate of recurrence by >40% at 24 months
Slide 21: YUTIQ Safety: Selected Ocular Adverse Events
YUTIQ Safety: Selected Ocular Adverse Events Safety, n (%) YUTIQTM n=226 Placebo n=94 Visual Acuity Reduced 33 (15%) 11 (12%) Macular Edema1 25 (11) 33 (35) Uveitis 22 (10) 33 (35) Conjunctival Hemorrhage 17 (8) 5 (5) Eye Pain2 17 (8) 12 (13) Hypotony of the Eye3 16 (7) 1 (1) Anterior Chamber Inflam
Slide 22: YUTIQ Commercial Launch Approach
YUTIQTM Commercial Launch Approach Launched on February 4, 2019 Longest duration product indicated for chronic non-infectious uveitis Non-disruptive / corticosteroids remain current standard of care Goal of treatment is to prevent flares that can lead to blindness 10 KAMs solely focused on YUTIQTM J
Slide 23: YUTIQ 6mo vs. 3yr Implant in Vitro Release Rate Comparison
YUTIQ™ 6mo vs. 3yr Implant in Vitro Release Rate Comparison Long term in vitro release rate matched with the 3-year insert Note 1: Study conducted in rabbit eyes. Note 2: Release rate compared to rate meeting specifications for stability of clinical lot used in Iluvien clinical trials at pre-determi
Slide 24: Company Milestones & Strategy
Company Milestones & Strategy DEXYCUTM launched on March 12, 2019 YUTIQTM launched February 4, 2019 YUTIQTM 6-month formulation sNDA submission in 2019 Continued development and progression Durasert™ TKI Potential partnerships surrounding Durasert™ and Verisome® technologies Evaluating in-licensing
Slide 25: Financial Highlights
Financial Highlights * A $15.0 million milestone payment to former shareholders of Icon Bioscience is triggered upon the first commercial sale of DEXYCUTM. Note: Please refer to the Company’s filings on EDGAR for further detail. Cash $48.5 million as of February 28, 2019* Debt Up to $60.0 million fa
Slide 26: EyePoint Highlights: Transformational Opportunity in Ophthalmology
Evaluate potential partnerships surrounding Durasert™ and Verisome® technologies Launched YUTIQTM (Feb 4, 2019) and DEXYCUTM (Mar 12, 2019) (J-Code reimbursement in place for both products) Utilize our platform to progress assets that address unmet medical needs (YUTIQTM 6-month formulation, Duraser
EyePoint Pharmaceuticals — Investor Presentation (April 2019) on 6ix